You are here

Publications

Found 67 results
[ Author(Desc)] Title Type Year
Filters: First Letter Of Last Name is M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Moore JP, Klasse PJ.  2020.  COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.. J Virol. 94(17)
Moore JP, Kuritzkes DR.  2009.  A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.. Curr Opin HIV AIDS. 4(2):118-24.
Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J et al..  2005.  Ancestral antibiotic resistance in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 102(34):12200-5.
Mosior J, Bourland R, Soma S, Nathan C, Sacchettini J.  2019.  Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis.. Protein Sci.
Müller S, Wolf AJ, Iliev ID, Berg BL, Underhill DM, Liu GY.  2015.  Poorly Cross-Linked Peptidoglycan in MRSA Due to mecA Induction Activates the Inflammasome and Exacerbates Immunopathology.. Cell Host Microbe. 18(5):604-12.
Mundhra S, Bryk R, Hawryluk N, Zhang T, Jiang X, Nathan C.  2018.  Evidence for dispensability of protein kinase R in host control of tuberculosis.. Eur J Immunol. 48(4):612-620.
Murakami M, Francavilla C, Torselli I, Corada M, Maddaluno L, Sica A, Matteoli G, Iliev ID, Mantovani A, Rescigno M et al..  2010.  Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration.. Cancer Res. 70(5):1759-65.
Murphy M, Gomos-Klein J, Stankic M, Falck-Pedersen E.  2007.  Adeno-associated virus type 2 p5 promoter: a rep-regulated DNA switch element functioning in transcription, replication, and site-specific integration.. J Virol. 81(8):3721-30.
Murray HW, Mitchell-Flack M, Taylor GA, Ma X.  2015.  IFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.. Exp Parasitol. 157:103-9.
Murray HW, Xiang Z, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.. Am J Trop Med Hyg. 74(6):1013-5.
Murray HW, Luster AD, Zheng H, Ma X.  2017.  Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.. Infect Immun. 85(1)
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.. Infect Immun. 74(7):4370-4.
Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, Heinzel FP.  2003.  Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.. J Infect Dis. 188(3):458-64.
Murray HW, Zhang Y, Zhang Y, Raman VS, Reed SG, Ma X.  2013.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.. Infect Immun. 81(7):2318-26.
Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, Ma X.  2005.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.. Infect Immun. 73(7):3903-11.
Murray HW, Mitchell-Flack M, Zheng H, Ma X.  2015.  Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.. Infect Immun. 83(2):702-12.
Murray HW, Tsai CW, Liu J, Ma X.  2006.  Visceral Leishmania donovani infection in interleukin-13-/- mice.. Infect Immun. 74(4):2487-90.